top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

David Rosenbaum Biography and Net Worth

Insider of Ardelyx

Dr. David P. Rosenbaum, Ph.D. is Chief Development Officer of the Company. From 2003 to 2008, he was Vice President of Drug Development for Trine Pharmaceuticals, Inc., a biopharmaceutical company, where he was developing a novel non-systemic therapeutic for the treatment of IBS. In addition, Dr. Rosenbaum previously served as Vice President of Preclinical Research and Development at GelTex Pharmaceuticals, a biopharmaceutical company, where he was responsible for the preclinical development of Renagel and Welchol. He received a B.A. in Biology from the University of Pennsylvania, a M.S. in Toxicology from Albany Medical College and a Ph.D. in Pharmacology from Boston University School of Medicine.

What is David P. Rosenbaum's net worth?: The estimated net worth of David P. Rosenbaum is at least $1.13 million as of February 26th, 2024. Dr. Rosenbaum owns 175,936 shares of Ardelyx stock worth more than $1,131,268 as of April 25th. This net worth estimate does not reflect any other assets that Dr. Rosenbaum may own. Additionally, Dr. Rosenbaum receives an annual salary of $645,400.00 as Insider at Ardelyx. Learn More about David P. Rosenbaum's net worth.
How old is David P. Rosenbaum?: Dr. Rosenbaum is currently 63 years old. There are 6 older executives and no younger executives at Ardelyx. The oldest executive at Ardelyx is Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer, who is 64 years old. Learn More on David P. Rosenbaum's age.
What is David P. Rosenbaum's salary?: As the Insider of Ardelyx, Inc., Dr. Rosenbaum earns $645,400.00 per year. There are 3 executives that earn more than Dr. Rosenbaum. The highest earning executive at Ardelyx is Mr. Michael G. Raab, President, CEO & Director, who commands a salary of $1,280,000.00 per year. Learn More on David P. Rosenbaum's salary.
How do I contact David P. Rosenbaum?: The corporate mailing address for Dr. Rosenbaum and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on David P. Rosenbaum's contact information.
Has David P. Rosenbaum been buying or selling shares of Ardelyx?: David P. Rosenbaum has not been actively trading shares of Ardelyx during the past quarter. Most recently, David P. Rosenbaum sold 5,183 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $9.20, for a transaction totalling $47,683.60. Following the completion of the sale, the insider now directly owns 175,936 shares of the company's stock, valued at $1,618,611.20. Learn More on David P. Rosenbaum's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, insiders at the biopharmaceutical company sold shares 31 times. They sold a total of 643,508 shares worth more than $3,874,269.01. The most recent insider tranaction occured on April, 15th when CEO Michael Raab sold 7,500 shares worth more than $52,950.00. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 4/15/2024.

David P. Rosenbaum Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2024	Sell	5,183	$9.20	$47,683.60	175,936
2/8/2024	Sell	15,344	$9.18	$140,857.92	384,002
1/8/2024	Sell	30,000	$6.64	$199,200.00	286,596
12/18/2023	Sell	5,675	$6.07	$34,447.25	316,596
12/14/2023	Sell	7,000	$5.55	$38,850.00	322,271
12/8/2023	Sell	20,000	$5.27	$105,400.00	329,271
12/5/2023	Sell	10,272	$5.00	$51,360.00	349,271
11/30/2023	Sell	3,000	$4.50	$13,500.00	359,543
10/10/2023	Sell	1,644	$4.00	$6,576.00	365,378
9/8/2023	Sell	2,897	$4.55	$13,181.35	367,022
3/29/2023	Sell	3,000	$4.63	$13,890.00	113,096
5/20/2022	Sell	1,489	$0.67	$997.63	347,920
11/22/2021	Sell	643	$0.99	$636.57
8/20/2021	Sell	631	$1.32	$832.92	158,804
5/28/2021	Sell	3,062	$7.22	$22,107.64	159,435
5/20/2021	Sell	612	$7.09	$4,339.08	159,435
4/6/2021	Sell	5,000	$8.00	$40,000.00	160,047
6/4/2019	Sell	2,856	$2.54	$7,254.24
1/2/2019	Sell	5,585	$1.70	$9,494.50	160,027
11/13/2018	Sell	5,570	$2.84	$15,818.80
4/18/2017	Sell	2,051	$11.98	$24,570.98
12/16/2016	Sell	900	$14.48	$13,032.00	22,144
9/22/2015	Sell	1,400	$22.05	$30,870.00	25,880
9/15/2015	Sell	2,540	$22.01	$55,905.40	25,880
9/3/2015	Sell	2,537	$18.78	$47,644.86	25,880

David P. Rosenbaum Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $6.43

$6.39

$6.66

50 Day Range

MA: $7.96

$6.39

$9.67

2 Week Range

Now: $6.43

$3.16

$10.13

Volume

5,455,146 shs

Average Volume

6,074,723 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

David Rosenbaum Biography and Net Worth

What is David P. Rosenbaum's net worth?

How old is David P. Rosenbaum?

What is David P. Rosenbaum's salary?

How do I contact David P. Rosenbaum?

Has David P. Rosenbaum been buying or selling shares of Ardelyx?

Who are Ardelyx's active insiders?

Are insiders buying or selling shares of Ardelyx?